Of course, the concept of a possible dose-dependent association between FABP4 and the myocardium is completely speculative, and the majority of the publications so far does not support a beneficial association of effect of FABP4 not only on the heart but other systems: FABP4 has been described to have adverse association with insulin resistance, diabetes and the metabolic syndrome, [3–6], and with atherosclerosis and cardiovascular diseases, [1, 7] and sodium glucose cotransporter 2 inhibitors might have a beneficial effect via decreased FABP4 expression on perivascular adipose tissue [10]. The gene discussed is FABP4; the disease is cardiovascular disorder.